NRAS and neoplasm: To investigate whether the NRAS mutations were already present in the tumor before immunotherapy on a subclonal level, we searched for a low frequency presence of the NRAS mutations in the sequencing data from the investigated tissue punches (mean coverage of coding target region: patient 1: 168x (primary diagnosis) and 791x (extensive resection); patient 2: 757x; patient 3: 1371x) but did not find any.